Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Donepezil Hydrochloride Clear all
Completed Phase 2 Interventional

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

NCT00884507
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, RO5313534
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Orange, California • Torrance, California • Norwalk, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 6, 2026, 10:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336
View directory record Official record
Conditions
Biomarkers, Pharmacological
Interventions
Huperzine A, Donepezil, Galantamine, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

NCT00916383
View directory record Official record
Conditions
Irritation/Irritant
Interventions
350 mg Donepezil Transdermal Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 6, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398
View directory record Official record
Conditions
Alzheimer Disease
Interventions
lecozotan SR, Donepezil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

NCT00408525
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donepezil
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

NCT00688376
View directory record Official record
Conditions
Attention Impairment
Interventions
Donepezil hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 6, 2026, 10:48 PM EDT
Withdrawn Phase 2 Interventional

CPC-201 Alzheimer's Disease Type Dementia: PET Study

NCT02860065
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201, Positron emission tomography (PET)
Drug · Other
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations

NCT03432195
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil TDS
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
30 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions

NCT01276067
View directory record Official record
Conditions
Healthy
Interventions
Donepezil
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Donepezil in Preventing Delirium in Hospitalized Elderly

NCT00182884
View directory record Official record
Conditions
Postoperative Complications, Delirium
Interventions
Donepezil
Drug
Lead sponsor
Indiana University Health
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 6, 2026, 10:48 PM EDT
Not listed Phase 1 Interventional

Aricept to Improve Functional Tasks in Vascular Dementia

NCT00457769
View directory record Official record
Conditions
Stroke, Vascular Dementia, Memory Deficits
Interventions
Donepezil and self-generated memory training, Donepezil and experimenter-administered memory training
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 6, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 3 Interventional

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799
View directory record Official record
Conditions
Traumatic Brain Injury, Memory Deficits
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 4 Interventional Results available

Neural Correlates In Mild Alzheimer's Disease

NCT00477659
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

VI-1121 for the Treatment Alzheimer's Disease

NCT01428362
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VI-1121, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

NCT06903910
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil (Aricept)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 6, 2026, 10:48 PM EDT
Terminated Phase 4 Interventional Results available

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

NCT01495195
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

NCT02822573
View directory record Official record
Conditions
Cognitive Dysfunction, Memory Impairment
Interventions
Donepezil 5 mg, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
278
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 206 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 6, 2026, 10:48 PM EDT
Completed Phase 4 Interventional

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

NCT00315367
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Donepezil HCI (drug)
Drug
Lead sponsor
Neurognostics
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 6, 2026, 10:48 PM EDT